News in brief

Osteoarthritis and metabolic disease: a “joint” therapeutic target?

21 Jun 2017 - 12h54 | By INSERM PRESS OFFICE | Circulation, metabolism, nutrition

© Fotolia

Osteoarthritis is an incapacitating condition with diverse etiologies, the most recently described of which is metabolic syndrome (MetS). For the first time, researchers from the “Molecular Engineering and Articular Physiopathology” (Cnrs/Université de Lorraine) and “Acute and chronic cardiovascular failure” (Inserm/Université de Lorraine) research laboratories in Nancy, France, have described the spontaneous development of this type of degenerative joint disease in a mouse model of MetS. Inserm researchers Hervé Kempf and Anne Pizard, together with their co-workers, have characterized the existence of osteoarthritic lesions of the tibiofemoral joint of the knee in the presence of metabolic disorders.

This new experimental model of metabolic-associated osteoarthritis has also made it possible to demonstrate that chronic treatment with a mineralocorticoid receptor antagonist (MCRA) improves joint impairment. This drug is already used in heart failure and has been proposed as possibly being more effective in obese patients.

This research has been the subject of a letter published in Annals of the Rheumatic Diseases.

For the researchers, “these results will make it possible to propose metabolic-associated osteoarthritis as a potential new indication for MCRA therapy”, a hypothesis that they intend to test in the clinical setting very soon.

Inserm Transfert has filed a patent application for this research.

TO CITE THIS POST :
Inserm press room Osteoarthritis and metabolic disease: a “joint” therapeutic target? Link : http://presse.inserm.fr/en/osteoarthritis-and-metabolic-disease-a-joint-therapeutic-target/28799/
Medias
Researcher Contact

Hervé Kempf
Mixed Research Unit “Molecular Engineering and Articular Physiopathology”, Vandoeuvre-lès-Nancy, France
herve.kempf@inserm.fr
+33 (0) 3 83 68 54 26

Anne Pizard
Multi-theme CIC Unit 1433, Nancy University Hospital and INSERM U1116 “Acute and chronic cardiovascular failure”, Vandoeuvre-lès-Nancy, France
anne.pizard@inserm.fr
+33 (0) 3 83 15 52 97

Press Contact

presse@inserm.fr

+33 (0) 1 44 23 60 97

Sources

Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis, Annals of the Rheumatic Diseases

Chaohua Deng1,2, Arnaud Bianchi1,2, Nathalie Presle1,2, David Moulin1,2,3, Meriem Koufany1,2, Cécile Guillaume1, Anne Pizard2,3,4,5, Hervé Kempf1,2

  1. UMR7365 CNRS-Université de Lorraine, IMoPA, Ingénierie Moléculaire et Physiopathologie Articulaire, Vandoeuvre-les-Nancy, France
  2. Fédération de Recherche 3209, Vandoeuvre-les-Nancy, France
  3. CHRU Nancy, Vandoeuvre-les-Nancy, France
  4. UMRS-Inserm U1116, Université de Lorraine, Vandoeuvre-les-Nancy, France
  5. CIC-P1433 Inserm, CHRU Nancy, Vandoeuvre-les-Nancy, France

BMJ Journal

fermer
fermer
RSS Youtube